Dassault Systèmes Buys Drug Trial Software Maker ArisGlobal for $2 Billion to Expand Life Sciences and AI Offerings

businessmergers-acquisitions 4 posts · 4 accounts

Dassault Systèmes agreed to buy life sciences drug trial software maker ArisGlobal for up to $2 billion.

The transaction, which involves purchasing the U.S. supplier from Nordic Capital, will expand the French firm’s life sciences footprint and bolster its artificial intelligence capabilities. The deal is expected to close in the second half of 2026.

From the sources (4 posts)

@firstsquawk

Dassault Systemes to Buy ArisGlobal for Up to $2 Billion-WSJ

@wsj

The French company agreed to buy the U.S. supplier of software to the life-sciences industry, seeking to bolster its artificial-intelligence offering.

@business

Dassault Systèmes will buy drug trial software maker ArisGlobal for as much as $2 billion as the French firm expands its push into life sciences

@techmeme

Dassault Systèmes agrees to acquire ArisGlobal, a US supplier of software to the life sciences industry, from Nordic Capital for ~$2B, set to close in H2 2026 (Adrià Calatayud / Wall Street Journal) (Visit Techmeme dot com for the link and

Kpler Analysts Track Global Oil on Water to Record 1.35 Billion Barrels, Capping Rally UK, US Cyber Evaluators Test Kimi K3 on Security Benchmarks; Scores 32% on Exploit Tool, Trails Frontier Models